327 related articles for article (PubMed ID: 26673145)
1. Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.
Ligtenberg MA; Mougiakakos D; Mukhopadhyay M; Witt K; Lladser A; Chmielewski M; Riet T; Abken H; Kiessling R
J Immunol; 2016 Jan; 196(2):759-66. PubMed ID: 26673145
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
6. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.
Krug C; Wiesinger M; Abken H; Schuler-Thurner B; Schuler G; Dörrie J; Schaft N
Cancer Immunol Immunother; 2014 Oct; 63(10):999-1008. PubMed ID: 24938475
[TBL] [Abstract][Full Text] [Related]
7. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
[TBL] [Abstract][Full Text] [Related]
8. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
Liu L; Sun M; Wang Z
Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
[TBL] [Abstract][Full Text] [Related]
10. Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress.
Renken S; Nakajima T; Magalhaes I; Mattsson J; Lundqvist A; Arnér ESJ; Kiessling R; Wickström SL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738800
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
[TBL] [Abstract][Full Text] [Related]
12. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
13. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.
Chen KH; Wada M; Firor AE; Pinz KG; Jares A; Liu H; Salman H; Golightly M; Lan F; Jiang X; Ma Y
Oncotarget; 2016 Aug; 7(35):56219-56232. PubMed ID: 27494836
[TBL] [Abstract][Full Text] [Related]
16. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
17. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer.
Chmielewski M; Abken H
Cancer Immunol Immunother; 2012 Aug; 61(8):1269-77. PubMed ID: 22274776
[TBL] [Abstract][Full Text] [Related]
18. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
19. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
20. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
